CNS Summit 2024: Neuronal plasticity markers in iPSC-Derived Neurons as a platform for drug response models in Alzheimer’s Disease

Neuronal plasticity markers in iPSC-Derived Neurons as a platform for drug response models in Alzheimer’s Disease

This collaborative study with NeuroSense Therapeutics highlights the use of iPSC-derived neurons from well-characterized Alzheimer’s Disease (AD) patients to support drug development strategies. The research focuses on profiling drug responses to the PrimeC combination (ciprofloxacin and celecoxib), offering insights into neuronal plasticity and potential therapeutic mechanisms for AD. This innovative approach aims to aid patient stratification, biomarker discovery, and precision treatment strategies for neurodegenerative diseases.

Key Highlights:

• iPSC-derived neurons differentiated into robust cortical neurons with AD-specific markers.

• PrimeC treatment evaluated for effects on neuronal plasticity and therapeutic potential.

• Supports the development of predictive models for patient-specific treatment strategies.